SCHEMBL26826953

SCHEMBL26826953

Nc1ccc(O[C@H]2C[C@@H](O)C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP3A4 P08684 2/20 0.42
TSHR P16473 2/20 0.42
FURIN P09958 2/20 0.41
MAPK1 P28482 1/20 0.39
SLC6A4 P31645 4/20 0.39
SLC6A2 P23975 3/20 0.39
SLC6A3 Q01959 3/20 0.39
PARP10 Q53GL7 2/20 0.39
SENP8 Q96LD8 2/20 0.38
SENP6 Q9GZR1 2/20 0.38
MAOA P21397 2/20 0.37
MAPT P10636 2/20 0.35
TEAD4 Q15561 1/20 0.35
MAOB P27338 1/20 0.35
LMNA P02545 1/20 0.35
CASP3 P42574 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26675778 1.00 TDP1 (0.42) TDP1ALDH1A1CYP3A4TSHRFURIN
SCHEMBL26675785 1.00 TDP1 (0.42) TDP1ALDH1A1CYP3A4TSHRFURIN
Hydrochloric Acid SCHEMBL26675788 0.98 TDP1 (0.41) TDP1ALDH1A1CYP3A4TSHRFURIN
Hydrochloric Acid SCHEMBL26675783 0.98 TDP1 (0.41) TDP1ALDH1A1CYP3A4TSHRFURIN
SCHEMBL31585029 0.81 EPHX2 (0.44)
SCHEMBL13724423 0.81 PARP10 (0.46) TDP1ALDH1A1CYP3A4TSHRFURIN
SCHEMBL25361519 0.78 LTA4H (0.42) ALDH1A1TSHRFURINSLC6A4SLC6A2
SCHEMBL26098186 0.77 GRIN1 (0.43) ALDH1A1TSHRFURINMAPK1SLC6A4
SCHEMBL6903727 0.77 TDP1 (0.50) TDP1ALDH1A1CYP3A4TSHRFURIN
SCHEMBL8314928 0.77 TDP1 (0.50) TDP1ALDH1A1CYP3A4TSHRFURIN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382909-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-30 US disclosed
US-20230382909-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382909-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 TDP1 3822/4885ALDH1A1 543/4885CYP3A4 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.